lt is a dual glucose-dependent insulinotropic polypeptide (GIPand glucagon-like peptide-1 (GLP-1)
receptor agonist that is beingdeveloped for the treatment of type 2 diabetes. lt shows significantlybetter 
efficacy with regard to glucose control.

Thiscontent is provided strictly for research purposes and does not constitute anendorsement or 
recommendation for the non-laboratoryapplication or improper handling of peptides designed for research. The information, including discussions about specific peptides and theirresearched benefits, is presented for informational purposes only and must notbe construed as health, clinical, or legal guidance, nor an encouragement fornon-research use in humans,
Peptides described here are solely for use instructured scientific study by authorized individuals,

Forresearch USE ONLY,

Certificate